Pre-made Futuximab benchmark antibody ( Whole mAb, anti-EGFR therapeutic antibody, Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-227
Pre-Made Futuximab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Futuximab (992 DS) (INN) is a chimeric monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and also binds to HER1.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||List Price(In USD)||Discount off||Discount Price|
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)||Pre-Made Futuximab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Colorectal cancer;Glioma;Non-small cell lung cancer|
|Conditions Discontinued||Head and neck cancer;Oesophageal cancer|